Algorithmic Approach to a Child with Suspected Immune Dysfunction

Algorithm

%%{init: {"themeVariables": { "lineWidth": "3px", "lineColor": "#000000" } }}%%
flowchart TD
    %% Custom class definitions for high-contrast, color-coordinated nodes
    classDef flag fill:#ffe4e6,stroke:#e11d48,stroke-width:2px,color:#881337;
    classDef level1 fill:#e0f2fe,stroke:#0284c7,stroke-width:2px,color:#0c4a6e;
    classDef decision fill:#fef08a,stroke:#ca8a04,stroke-width:2px,color:#713f12;
    classDef level2 fill:#dcfce7,stroke:#16a34a,stroke-width:2px,color:#14532d;
    classDef level3 fill:#f3e8ff,stroke:#9333ea,stroke-width:2px,color:#4c1d95;

    A[Clinical Recognition & Suspicion
Red Flags: Severe/opportunistic infections, family history,
consanguinity, adverse live vaccine reactions]:::flag

    A --> B(Step 1: Initial Basic Screening - Level 1):::level1

    B --> B1[Newborn Screening
TREC & KREC PCR assays from dried blood spots]:::level1
    B --> B2[CBC & Peripheral Smear
Evaluate for lymphopenia, neutropenia,
Howell-Jolly bodies, giant lysosomal granules]:::level1
    B --> B3[Quantitative Igs & Antibodies
IgG, IgA, IgM, IgE & functional titers
vs. protein/polysaccharide antigens]:::level1
    B --> B4[Global Complement Screening
CH50 & AH50/AP50 functional assays]:::level1

    B1 --> C{Abnormal screening OR
high clinical suspicion?}:::decision
    B2 --> C
    B3 --> C
    B4 --> C

    C -->|Yes| D(Step 2: Targeted Pathway-Specific Evaluation - Level 2):::level2

    D --> E[Suspected Humoral Defect
Flow Cytometry: CD19, CD20
Advanced: Naive & class-switched memory B-cells
23-valent pneumococcal vaccine response]:::level2
    D --> F[Suspected Combined/T-Cell Defect
Flow Cytometry: CD3, CD4, CD8, CD16, CD56
Lymphocyte proliferation to mitogens/antigens
Cytokine ELISPOT & NK cytotoxicity assays]:::level2
    D --> G[Suspected Phagocytic Defect
DHR reduction assay for CGD
Evaluate eosinophils to distinguish MPO deficiency
Flow Cytometry: CD11b, CD18, CD15 for LAD]:::level2
    D --> H[Suspected Complement Defect
Immunochemical tests: C3, C4, properdin, MBL
Activation split fragments to distinguish consumption
Flow Cytometry: CD55, CD59 for PNH]:::level2

    E --> I(Step 3: Advanced Molecular & Genetic Testing - Level 3):::level3
    F --> I
    G --> I
    H --> I

    I --> J[Genetic Sequencing
Targeted SCID/PID Panels
Whole Exome or Whole Genome Sequencing]:::level3
    
    J --> K[Clinical Integration
Genetic Counseling, Prognostication,
Targeted Biologics, HSCT, Cellular Gene Therapy]:::level3

Clinical Recognition And Suspicion

The initial diagnosis of primary immune deficiency diseases is frequently delayed. This delay occurs because the individual disease incidence is rare and there is often a low index of suspicion. The presenting symptoms can easily mimic common, non-specific childhood illnesses.

Physicians must be acutely aware of specific clinical red flags. These red flags mandate a thorough immunologic evaluation. A high burden of recurrent or sentinel infections is the most common reason to initiate an immunologic workup.

10 Clinical Red Flags for Primary Immunodeficiency (PID)

According to the Jeffrey Modell Foundation and international expert consensus, the following clinical features should raise suspicion of a Primary Immunodeficiency in pediatric patients:

1. Eight or more new ear infections within one year.
2. Two or more serious sinus infections within one year.
3. Two or more months of antibiotics with little effect.
4. Two or more pneumonias within one year.
5. Failure of an infant to gain weight or grow normally.
6. Recurrent, deep skin or organ abscesses.
7. Persistent thrush in the mouth or fungal infection on the skin after age one.
8. Need for intravenous antibiotics to clear infections.
9. Two or more deep-seated infections including septicemia.
10. A family history of primary immunodeficiency.

Clinical Clues Guiding The Diagnostic Algorithm

Specific patterns of infection and physical findings help guide the initial laboratory evaluation toward a specific compartment of the immune system.

Step 1: Initial Basic Screening (Level 1 Testing)

The first level of testing relies on broadly available screening tools. It begins in the neonatal period and extends to initial laboratory blood tests for symptomatic children.

Newborn Screening

• Newborn screening enables the early detection of severe combined immunodeficiency before symptoms arise.
• The screening heavily relies on a quantitative polymerase chain reaction assay.
• This assay measures T-cell receptor excision circles from dried blood spots.
• T-cell receptor excision circles are DNA byproducts formed during the V(D)J rearrangement of T-cell receptor chains.
• They do not replicate during cell division.
• Therefore, they serve as an accurate marker for quantifying recent thymic emigrants.
• A low or absent count raises high suspicion for severe combined immunodeficiency.
• In some regions, kappa excision circles are assayed simultaneously.
• Kappa excision circles identify infants with severe B-cell defects, such as congenital agammaglobulinemia.

Complete Blood Count And Peripheral Smear

• For symptomatic children, basic screening must begin with a complete blood count with differential.
• Persistent lymphopenia is a critical finding.
• Lymphopenia strongly suggests severe combined immunodeficiency or another combined T-cell defect.
• Severe neutropenia provides diagnostic clues for congenital phagocytic disorders.
• A marked neutrophilic leukocytosis without obvious pus formation is a hallmark of leukocyte adhesion deficiency.
• The peripheral blood smear must be carefully reviewed.
• Howell-Jolly bodies on a smear indicate isolated congenital asplenia.
• The presence of giant lysosomal granules establishes the diagnosis of Chédiak-Higashi syndrome.

Quantitative Immunoglobulins And Specific Antibodies

• Quantitative serum immunoglobulin levels must be accurately measured.
• This specifically includes the measurement of IgG, IgA, IgM, and IgE.
• Patient values must be compared to age-matched and race-matched normal values.
• Assessing antibody responses to prior routine vaccinations evaluates functional antibody production.
• Functional capacity is tested by measuring titers against protein antigens like diphtheria and tetanus.
• Functional capacity is also tested against polysaccharide antigens like pneumococcus.

Global Complement Screening

• The total hemolytic complement activity assay serves as the best initial screening test.
• The CH50 assay screens the functional activity of the classical complement pathway.
• It measures the complement-mediated lytic destruction of antibody-sensitized sheep erythrocytes.
• The AH50 or AP50 assay screens the functional activity of the alternative complement pathway.

Step 2: Targeted Pathway-Specific Evaluation (Level 2 Testing)

If the initial basic screening reveals abnormalities, the algorithm branches into specific, targeted evaluations. This targeted approach is also warranted if clinical suspicion remains high despite completely normal initial screening tests.

Evaluation Of Suspected Antibody (Humoral) Deficiencies

• Flow cytometry is strictly essential to demonstrate the presence or absence of circulating B cells.
• It utilizes specific surface markers, primarily CD19 and CD20, to enumerate B-cell populations.
• A complete absence of CD19+ B cells confirms congenital agammaglobulinemia, such as X-linked agammaglobulinemia.
• Specific antibody deficiency is suspected in patients over 2 years of age who have normal total immunoglobulins but suffer recurrent infections.
• The gold standard for diagnosing specific antibody deficiency involves evaluating the response to the 23-valent pneumococcal polysaccharide vaccine.
• An antibody titer of 1.3 mg/mL is generally considered the protective threshold.
• Advanced flow cytometry is utilized to enumerate specific percentages of naive B cells, memory B cells, and class-switched memory B cells.
• A deficiency in class-switched memory B cells helps diagnose common variable immunodeficiency.

Evaluation Of Suspected Cell-Mediated (T-Cell And Combined) Deficiencies

• Flow cytometry precisely quantifies total T lymphocytes and their specific subsets.
• Markers used include CD3 for total T cells, CD4 for T-helper cells, and CD8 for cytotoxic T cells.
• The ratio of CD4+ to CD8+ T cells is calculated.
• Significant alterations in this ratio can indicate an underlying immunodeficiency.
• Flow cytometry distinguishes naive T cells (CD45RA) from memory T cells (CD45RO).
• This differentiation helps identify conditions like maternal engraftment or Omenn syndrome.
• Natural killer cells are enumerated using surface markers CD16 and CD56.

Functional Assays For T-Cell And Natural Killer Cell Activity

Evaluation Of Suspected Phagocytic Defects

• Functional evaluation of the neutrophil respiratory burst screens for chronic granulomatous disease.
• The dihydrorhodamine reduction assay via flow cytometry is the gold standard diagnostic test.
• It evaluates oxidant production through increased fluorescence.
• The fluorescence increases when the dye is successfully oxidized by intracellular hydrogen peroxide.
• This flow cytometric assay has largely replaced the older nitroblue tetrazolium slide test.
• Severe myeloperoxidase deficiency can cause a falsely positive dihydrorhodamine result for neutrophils.
• Evaluating the patient's eosinophils reliably differentiates the two conditions.
• Eosinophils still reduce dihydrorhodamine normally in myeloperoxidase deficiency, but they fail to do so in chronic granulomatous disease.
• If a leukocyte adhesion deficiency is suspected, flow cytometry evaluates specific surface adhesive glycoproteins.
• The diagnosis of type 1 deficiency relies on demonstrating the absence or severe reduction of CD11b and CD18.
• The diagnosis of type 2 deficiency relies on demonstrating the specific absence of the sialyl Lewis X antigen (CD15).

Evaluation Of Suspected Complement Deficiencies

• A negative or abnormally low CH50 or AH50 screening assay mandates specific immunochemical tests.
• These tests are required to define the precise underlying defect.
• Radial immunodiffusion, enzyme-linked immunosorbent assays, and nephelometry are utilized.
• These techniques definitively quantify individual complement components such as C3, C4, properdin, and mannose-binding lectin.
• It is crucial to distinguish primary genetic defects from acquired complement consumption.
• Acquired consumption frequently occurs in active immune complex diseases.
• This distinction relies on measuring specific complement activation products and split fragments.
• These measured fragments include C3a, C4d, Ba, Bb, and the soluble terminal complement complex sC5b-9.
• If paroxysmal nocturnal hemoglobinuria is suspected, flow cytometry is the standard diagnostic technique.
• It detects abnormally reduced surface levels of specific complement regulatory proteins, namely CD55 and CD59.

Step 3: Advanced Molecular And Genetic Testing (Level 3 Testing)

Targeted genetic testing serves as the final and most definitive step in the diagnostic algorithm.

Modalities And Utility

• Targeted gene sequencing is the most definitive method of diagnosis for the vast majority of primary immunodeficiency disorders.
• Sequencing is frequently performed by requesting a specific severe combined immunodeficiency gene panel.
• Broader primary immunodeficiency gene panels, whole exome sequencing, or whole genome sequencing are routinely employed.
• Establishing a precise genetic etiology confirms the exact condition following abnormal functional laboratory results.

Clinical Application And Management Impact

• Identifying specific pathogenic gene variants provides accurate genetic counseling and allows for prenatal diagnosis.
• Genetic diagnosis predicts the clinical prognosis of the disease.
• In primary immune regulatory disorders, standard functional immunological testing is frequently completely normal.
• Therefore, next-generation sequencing is strictly necessary to establish a diagnosis in these immune regulatory conditions.
• Identifying the exact mutation provides crucial guidance for the use of targeted biological therapies.
• The specific variant also dictates the feasibility and conditioning requirements for definitive treatments.
• Such definitive treatments frequently include hematopoietic stem cell transplantation or advanced cellular gene therapy.